About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT02164071

Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies

The elderly comprise the most prevalent population in oncology practice. The available evidence suggests that old patients are undertreated patients, mainly because of their advanced age, regardless o...

Lead sponsor: Celgene•22 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Celgene

Age

65 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients ≥ 65 years old. Treatment-naïve patients
•Newly diagnosed patients who belong to one of the 3 following groups:
•Patients with MDS (any risk grade as per IPSS) or AML Patients with multiple myeloma (symptomatic or not) or Patients with chronic lymphocytic leukemia (including A status) Patients who have granted their informed consent.

Exclusion Criteria

•Not fulfilling selection criteria

Related studies

RECRUITINGPhase 1/2

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

NCT06303193 · Myelodysplastic Syndromes

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma

RECRUITINGPhase 1

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

NCT06215118 · Multiple Myeloma

RECRUITINGPhase 2

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867 · Myelodysplastic Syndromes

RECRUITINGPhase 3

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 18, 2019Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment363

Start dateApr 2012

Last updatedNov 18, 2019

Condition

Myelodysplastic Syndromes Leukemia Myeloid Acute Multiple Myeloma Leuklemia, Lymphocytic, Chronic

Locations shown

Hospital Txagorritxu

Vitoria-Gasteiz, Alava

Hospital Sant Joan de Deu

Espluges de Llobregat, Barcelona

Hospital Duran I Reynals

L'Hospitalet de Llobregat, Barcelona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2019Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions